Joe Gantoss’ Post

We are pleased to share Medicenna President and CEO Fahar Merchant's presentation of the Company's clinical updates on MDNA11 at the Oncology Innovation Forum last month, ahead of the American Society of Clinical Oncology 2024 Meeting. MDNA11, being evaluated in the Phase 1/2 ABILITY-1 Study, is the only non-alpha beta-enhanced IL-2 immunotherapy in clinical development. MDNA11 continues to demonstrate its best-in-class potential with differentiated deep and durable single agent activity in patients with advanced solid tumors who have failed checkpoint therapy. Sachs Associates video below accompanies the presentation on MDNA11. Read the full release for more information: https://lnkd.in/dR44hYaW #Immunotherapy #Oncology #Biotech #ClinicalTrial #AdvancedTumors

EVERYONE LOVES CASE STUDIES? https://lnkd.in/gJjzpukQ Here’s one you won’t want to miss on Vaderis Therapeutics 👇 In just 6 years, Vaderis turned an idea into clinical POC, pioneering the first AKT inhibitor for HHT, a rare bleeding disorder. Key hurdles included repurposing cancer drugs for chronic use, defining trial endpoints from scratch, and securing regulatory and funding pathways. Wanna see the full analysis/case study? Access here (sub/trial access required): https://lnkd.in/gJjzpukQ Insights and analysis from: Nicholas Benedict, CEO of Vaderis Therapeutics AG Pierre Saint-Mezard, CSO of Vaderis Therapeutics AG Damien Picard, CMO of Vaderis Therapeutics Anne Eichmann, Ensign Professor of Medicine (Cardiovascular Medicine) and Professor of Cellular And Molecular Physiology, Yale University Stephen Hansen, Director of Biopharma Intelligence, BioCentury Inc. #orphanDrug #biotech #raredisease #drugdevelopment #biopharma

Getting an early start on #jpm2024 . Looking forward to today’s panel discussion!

CONFERENCE UPDATE: The abstract is available for Repare Therapeutics' presentation at ESMO GI from the Phase 1 MINOTAUR trial evaluating lunresertib in combination with FOLFIRI. Learn more here: https://lnkd.in/ebPvugmb #precisiononcology #syntheticlethality #clinicaltrials

With such brilliant panel of experts you just can't afford to miss this webinar! #ESMO #PrecisionOncology #biomarkers

Research analysts at Germany’s Sphene Capital GmbH estimated that each Vidac Pharma share represents a value of €4.90, initiating coverage of the shares with a Buy rating. The valuation – which represents vast upside from where the stock is trading today – is based on the assumption that Vidac will obtain market approval for VDA-1102, its most advanced therapeutic candidate, for actinic keratosis. “If the market entry with VDA-1102 succeeds in 2027 as we expect, we assume that the company will achieve profitability ratios like comparable pharmaceutical companies in a very short time,” the analysts said their 75-page strong report. Other points making Vidac attractive were its two-product pipeline, being a pioneer in treating actinic keratosis with the toposteric effect, application across a wide range of tumors, a stable shareholder structure, and a clear undervaluation by the market. To read the full report, go to our website: https://lnkd.in/da-3wkFm #cancer #biotech #onchology #science #vidacpharma

Congratulations to our long-time partner Viking Therapeutics, Inc. who announced positive 52-week histologic data from their Phase 2b voyage study of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). The study successfully achieved its primary endpoint after 12 weeks of treatment, and affirmed VK2809's potent effect on liver fat, along with its favorable tolerability and safety profile. Yesterday's results also highlighted that VK2809 achieved its secondary endpoints evaluating histologic changes assessed by hepatic biopsy after 52 weeks of treatment with VK2809. NASH is a very large potential market. If Viking is successful in their development of VK2809, the program will address a multi-billion dollar market opportunity. Ligand earns a 3.5% -7.5% royalty on potential sales of VK2809 as well as significant clinical, regulatory, and commercial milestones. Read the announcement here: https://prn.to/3KqU8fQ

Discover how we identify participants for our Decoy20 clinical trials at Indaptus Therapeutics. VP of Clinical Operations, Jeffery Nieves explains our thorough process, from collaborating with healthcare professionals across the US to conducting rigorous screenings. Learn about our dedicated approach to selecting the right patients for our studies. #ClinicalTrials #CancerResearch #PatientSafety #biotech #BladderCancer

Join the upcoming Fierce Pharma webinar, “Innovative Therapeutics: Challenges and Opportunities in Developing Drug Combinations,” at 11 am ET on Oct. 15 hosted by Clarivate’s Mike Ward. This session will explore the complexities of combination drug therapies, offering insights into optimizing dosing regimens, mitigating adverse drug interactions, and navigating regulatory pathways. https://bit.ly/3XUmaa1 Hear from industry leaders at Clarivate, iOnctura, NeuroSense Therapeutics, Olema Oncology, and Takeda as they discuss groundbreaking approaches to treating complex diseases through drug combinations. #DrugDevelopment #Webinar

𝐅𝐨𝐫𝐦𝐲𝐜𝐨𝐧 𝐬𝐭𝐚𝐫𝐭𝐬 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐩𝐫𝐨𝐠𝐫𝐚𝐦 𝐟𝐨𝐫 𝐅𝐘𝐁𝟐𝟎𝟔, 𝐚 𝐛𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫 𝐜𝐚𝐧𝐝𝐢𝐝𝐚𝐭𝐞 𝐟𝐨𝐫 𝐢𝐦𝐦𝐮𝐧𝐨-𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐛𝐥𝐨𝐜𝐤𝐛𝐮𝐬𝐭𝐞𝐫 𝐝𝐫𝐮𝐠 𝐊𝐞𝐲𝐭𝐫𝐮𝐝𝐚® (𝐏𝐞𝐦𝐛𝐫𝐨𝐥𝐢𝐳𝐮𝐦𝐚𝐛) “With the start of the clinical development program and the first patient in, we have reached a major #milestone. We are at the forefront of the development of a #pembrolizumab biosimilar. Our FYB206 project not only has immense commercial potential, but above all offers exceptional therapeutic options.”, commented Dr. Stefan Glombitza, CEO of Formycon AG. With the 𝐟𝐢𝐫𝐬𝐭 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐢𝐧 the Phase I clinical #trial, Formycon is among the first three biosimilar companies announcing entry into the #clinical #development phase for the #EU and #US market. For further #details, please check our corporate news published today: https://lnkd.in/eDBhBrUm #TeamFormycon #FYB206 #Biosimilar #PK #PD1 #Oncology